Search

Displaying results 7981 - 7990 of 10000 in total
  1. Drug

    Pam2csk4

    go.drugbank.com/drugs/DB16474
    Investigational

  2. Drug

    Apratastat

    go.drugbank.com/drugs/DB13020
    Investigational

    Tmi 005 is under investigation in clinical trial NCT00095342 (Study Evaluating TMI-005 in Active Rheumatoid Arthritis).

  3. Drug

    Lanabecestat

    go.drugbank.com/drugs/DB14814
    Investigational

    Lanabecestat is under investigation in clinical trial NCT03499041 (A Study of LY3314814 in Participants With Liver Impairment).

  4. Drug

    KRN-5500

    go.drugbank.com/drugs/DB15215
    Investigational

    KRN-5500 is under investigation in clinical trial NCT00002923 (KRN5500 in Treating Patients With Metastatic Solid Tumors).

  5. Drug

    Oplunofusp

    go.drugbank.com/drugs/DB15313
    Investigational

    DAS-181 is under investigation in clinical trial NCT00527865 (Single Dose Escalating Study of DAS181 in Adults).

  6. Drug

    BP-14979

    go.drugbank.com/drugs/DB16302
    Investigational

    BP-14979 is under investigation in clinical trial NCT01785147 (Efficacy and Safety of BP1.4979 in Smoking Cessation).

  7. Drug

    Quavonlimab

    go.drugbank.com/drugs/DB16422
    Investigational

    Quavonlimab is under investigation in clinical trial NCT03179436 (Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)).

  8. Drug

    Reloxiliase

    go.drugbank.com/drugs/DB17653
    Experimental

    Reloxiliase is a first-in-class, oral crystalline formulation of the oxalate-specific, microbial enzyme oxalate decarboxylase. It is being investigated for the treatment of hyperoxaluria.[A258823]

  9. Drug

    WP-1301

    go.drugbank.com/drugs/DB17702
    Experimental

    WP1301 is a synthetic peptide derived from hFVIII. It binds to an MHC class II molecule and is recognized by a Factor VIII-specific T cell.[L46138]

  10. Drug

    Imnopitant

    go.drugbank.com/drugs/DB21456
    Experimental

    Imnopitant is a small molecule drug. The usage of the INN stem '-pitant' in the name indicates that Imnopitant is a neurokinin NK1​ (substance P) receptor antagonist.